Combining immune-related adverse events and inflammatory profiles enhances prognostic accuracy in metastatic melanoma under PD-1-based therapy.

ABSTRACT:

Background

Immune checkpoint inhibitors (ICIs) have improved outcomes in advanced melanoma, yet predictive biomarkers for treatment response and survival remain limited. Immune-related adverse events (irAEs) are frequent during ICI therapy and have been associated with improved outcomes, while baseline inflammatory markers-such as C-Reactive protein (CRP) and neutrophil-to-lymphocyte ratio (NLR)-often predict poor prognosis. However, no study to date has systematically integrated irAE characteristics and blood-based inflammation profiles to evaluate their combined prognostic value across different therapy lines.

Methods

We retrospectively analyzed 231 patients with unresectable stage IIIC-IV melanoma treated with PD-1-based ICIs at the University Hospital Cologne (2015-2021)

SUBMITTER: Garmpis D 

PROVIDER: S-EPMC12521244 | biostudies-literature | 2025

REPOSITORIES: biostudies-literature